BRUSSELS, BELGIUM – JUNE, 13 2019 Univercells announced today that it has been awarded a $14.3 million grant by the Bill & Melinda Gates Foundation to increase the availability of measles and rubella (M&R) vaccines in low- and middle-income countries (LMICs). Univercells will adapt the process design of its proprietary NevoLine™ platform to deliver affordable M&R…
Leiden, the Netherlands, May 14, 2019 – Batavia Biosciences announced today that it will work together in a consortium including the European Vaccine Initiative and Stanford University, icddr,b, and headed by the University of Tokyo, to develop an epidemic preparedness vaccine against the Nipah virus. For this purpose, the University of Tokyo received a $31…
The European Union has awarded €15 million to the CardioReGenix consortium, as part of the Horizon2020 program. The research program is initiated to develop new gene therapy approaches for the treatment of heart disease. The program is coordinated by Professor Marinee Chuah from the Free University of Brussels (VUB) and includes thirteen international partners, including…
Leiden, The Netherlands, February 25, 2019 – Batavia Biosciences announced today that it received a $13.2 million grant from the Bill & Melinda Gates Foundation to manufacture clinical-grade inactivated polio vaccine (sIPV), using its newly developed low-cost polio vaccine manufacturing process (marketed as HIP-IPVTM) based on the NevoLine™ manufacturing technology developed by Univercells. In 2016,…
Univercells, a business-to-business provider focused on increasing the availability of affordable biologics to address global health challenges, announced today the commercial launch of its proprietary NevoLine™ bioproduction system for vaccines. The system was initially developed as part of a $12M Grand Challenges grant awarded by the Bill & Melinda Gates Foundation to deliver affordable inactivated polio vaccine (sIPV). Leading…
Leiden, December 11, 2018 – Batavia Biosciences announces today that the International AIDS Vaccine Initiative (IAVI) and Batavia Biosciences will work together under a grant to advance the development of a Lassa fever vaccine. With this grant, Batavia Biosciences will leverage its novel, highly intensified manufacturing technology to develop a low-cost, easy-to-implement manufacturing process. This…
We are proud to announce that Batavia Biosciences has again been awarded with an FD Gazelle Award 2018 by the leading Dutch financial newspaper, Financieel Dagblad as one of the fastest growing mid-sized companies of the Netherlands. It is the fourth time we have won an FD Gazelle Award and we hope that many more…
Today, GHP Announces Winners of the Healthcare & Pharmaceutical Awards 2018. We are very proud to announce that Batavia Biosciences has been awarded “Best Biopharmaceutical Contract Development & Manufacturing Company 2018”. According to GHP: “The awards are given solely on merit and were awarded to commend those most deserving for their ingenuity and hard work, distinguishing…
We are pleased to announce that Dr. Menzo Havenga has been awarded the title CEO OF THE YEAR 2018- CONTRACT DEVELOPMENT AND MANUFACTURING. The European CEO Awards organization celebrates global business leaders that are making major strides in their respective fields. The organization recognizes product, service, functional, strategic, and managerial innovation in companies and individuals showing commercial insight and market integrity….
We are very proud that our CEO, Menzo Havenga, has been decorated in the Order of Orange-Nassau for his scientific achievements and his contributions to society. The Order of Orange-Nassau is a civil and military Dutch Royal order of chivalry founded on April 4, 1892. Menzo received the decorations that come with this distinction from…